PARP1 and cancer: From the point of view of the proficiency of DNA damage repair, BRCA1-associated TNBCs are not a homogenous group; therefore, they should not be regarded as such when patients with this type of cancer are enrolled in clinical trials of neoadjuvant chemotherapy with cisplatin or PARP inhibitors.